Shares of Amgen Inc. AMGN slipped 1.37% to $272.05 Thursday, on what proved to be an all-around positive trading session for ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

Wellness company Pharmavite, owners of the Nature Made brand, officially opened its 225,000-square-foot, $250 million plant ...

Once-daily roflumilast foam significantly improves scalp and body psoriasis in 8 weeks and was well-tolerated in adolescents ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Interest in the future expansion of the Conejo Valley biotech hub is soaring. Ventura County’s 2nd District, the BioScience Alliance in Westlake Village, the Economic Development Collaborative in ...

Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2025, with sales up 9.4% year on year to ...

The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...

Shares of Alphamab Oncology plunged 14.4% to HK$6.28, leading declines in Hong Kong-listed pharmaceutical stocks.Meanwhile, ...